Hugel, Inc. (KOSDAQ:145020)
South Korea · Delayed Price · Currency is KRW 359,000
-1,000 (-0.28%)
Aug 8, 2025, 3:30 PM KST
SolarWinds Revenue
Hugel had revenue of 89.82B KRW in the quarter ending March 31, 2025, with 20.88% growth. This brings the company's revenue in the last twelve months to 388.56B, up 17.88% year-over-year. In the year 2024, Hugel had annual revenue of 373.05B with 16.69% growth.
Revenue (ttm)
388.56B
Revenue Growth
+17.88%
P/S Ratio
9.41
Revenue / Employee
659.70M
Employees
589
Market Cap
3,658.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 373.05B | 53.35B | 16.69% |
| Dec 31, 2023 | 319.70B | 38.02B | 13.50% |
| Dec 31, 2022 | 281.68B | 49.82B | 21.49% |
| Dec 31, 2021 | 231.86B | 20.82B | 9.87% |
| Dec 31, 2020 | 211.04B | 6.47B | 3.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| Peptron | 4.30B |
| PharmaResearch | 392.31B |
| HLB Co., Ltd. | 74.64B |